Key result
Apixaban successfully reduced a recalcitrant right atrial thrombus from 71 x 21 mm to 31 x 5 mm in a patient with endocardial fibroelastosis after warfarin therapy failed.
Why the study?
Due to the rarity of endocardial fibroelastosis in developed countries and a lack of evidence-based options, the optimal anticoagulation strategy for associated intracardiac thrombus is unclear.
Does apixaban reduce intracardiac thrombus size in a patient with endocardial fibroelastosis and atrial fibrillation compared to warfarin?
Case Report (n=1)
Does apixaban reduce intracardiac thrombus size in a patient with endocardial fibroelastosis and atrial fibrillation compared to warfarin?
Apixaban successfully reduced a large right atrial thrombus in a patient with endocardial fibroelastosis and atrial fibrillation that had previously enlarged despite therapeutic warfarin therapy.
Apixaban may reduce warfarin-refractory right atrial thrombi in endocardial fibroelastosis; leaves open comparative efficacy in prospective studies.
BACKGROUND: Endocardial Fibroelastosis is diffuse, accentuated proliferation of ventricular endocardium causing a rare form of restrictive cardiomyopathy in both children and adults. It is an incompletely understood cause of heart failure predominantly in Sub-Saharan Africa associated with high morbidity and mortality. Atrial fibrillation and thrombus formation are common accompanying complications and portend a poor prognosis. Due to rarity of the condition in the developed countries and lack of evidence based options, the optimal strategy for anticoagulation is unclear. CASE PRESENTATION: Herein, we describe a relatively asymptomatic patient with endocardial fibroelastosis who has been found to have atrial fibrillation and a large thrombus in the right atrium. Currently, there is no evidence-based strategy in the management of endocardial fibroelastosis-associated intracardiac thrombus. This case report illustrates a scenario by which the use of apixaban potentially benefited or prevented the thrombus formation compared with warfarin as demonstrated by imaging findings. CONCLUSIONS: The patients with endocardial fibroelastosis are at risk of developing intracardiac thrombus due to sticky substrate lining cardiac chambers while being relatively asymptomatic. No directed therapy is known for the management of heart failure and any complications of subsequent arrhythmias. The general recommendations follow those of same conditions in other hosts. Novel oral anticoagulant agents can be considered in the treatment of atrial thrombus in the appropriate settings.
No takes yet. Share an insight, caveat, or question.
Ozdemir et al. (2019) conducted a case report in Endocardial fibroelastosis with atrial fibrillation and intracardiac thrombosis (n=1). Apixaban vs. Warfarin was evaluated on Thrombus size reduction. Apixaban successfully reduced a recalcitrant right atrial thrombus from 71 x 21 mm to 31 x 5 mm in a patient with endocardial fibroelastosis after warfarin therapy failed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: